Sarah has 5+ years of experience strategically supporting clients across the life sciences industry. In particular, Sarah has deep familiarity within oncology, inflammation and fibrosis, and rare disease therapeutic areas. With experience across engagement types, Sarah’s primary strategic focus includes early asset, asset life cycle, and portfolio or therapeutic area planning. She enjoys serving as a critical thought partner to clients, leveraging content expertise and strategic insights to drive to actionable, innovative solutions.
Prior to joining ClearView, Sarah received her Ph.D. in Chemical and Biomolecular Engineering from the University of Pennsylvania, where her thesis work centered on the development and application of human biomimetic angiogenesis models to study disease and development. Sarah received her B.S. in Chemical Engineering from the University of Washington.
Debbi Amanti Belanger